Propel Bio Management, LLC
CIK 1969764 · View on SEC EDGAR ↗
- Portfolio value
- $191.1M
- Positions
- 29
- As of
- June 30, 2026
#6,602 of 9,443 by 13F value · top 69.9%
Portfolio value QoQ: +20.4% 13F does not disclose cash
- Top 10 holdings weight
- 68.15%
- Top 25 holdings weight
- 97.54%
- Positions above 1%
- 25
- Effective number of positions
- 14.1
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 20.08% Est. buys $35,115,060 · sells $39,446,436
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 46.0% still held
- New positions
- 4
- Increased
- 11
- Decreased
- 10
- Closed
- 13
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +33.7% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 97.8% · Options excluded: 0.0%
Sector breakdown
Healthcare
79.3%
Energy
16.2%
Other/Unmapped
4.5%
Full portfolio 29 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PAGP Plains GP Holdings, L.P. - Class A Shares representing limited partner interests | $30,880,177 | 16.16% | 1,272,360 | $699,798 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $26,342,138 | 13.79% | 4,034,018 | $14,973,146 | Up ×1 | ||
| CORT Corcept Therapeutics Incorporated - Common Stock | $11,868,588 | 6.21% | 136,499 | $5,846,577 | Down ×1 | ||
| PHAT Phathom Pharmaceuticals, Inc. - Common Stock | $11,396,384 | 5.96% | 1,050,358 | $2,041,981 | Up ×3 | ||
| DCTH Delcath Systems, Inc. - Common Stock | $10,971,681 | 5.74% | 871,460 | $1,812,191 | Down ×1 | ||
| MIST Milestone Pharmaceuticals Inc. - Common Shares | $9,955,651 | 5.21% | 7,429,590 | $4,874,080 | Up ×1 | ||
| CMPS COMPASS Pathways Plc - American Depository Shares | $8,109,167 | 4.24% | 573,086 | $3,991,321 | Down ×2 | ||
| KYTX Kyverna Therapeutics, Inc. - Common Stock | $7,869,294 | 4.12% | 883,198 | $2,283,706 | Up ×1 | ||
| ARTV Artiva Biotherapeutics, Inc. - Common Stock | $6,755,429 | 3.54% | 696,436 | $5,805,611 | Up ×1 | ||
| ABEO Abeona Therapeutics Inc. - Common Stock | $6,075,373 | 3.18% | 983,070 | $67,391 | Down ×1 | ||
| AQST Aquestive Therapeutics, Inc. - Common Stock | $6,000,372 | 3.14% | 1,442,397 | $3,049,772 | Up ×1 | ||
| PALI Palisade Bio, Inc. - Common Stock | $5,397,191 | 2.82% | 2,582,388 | $3,400,441 | Up ×1 | ||
| Unknown issuer (CUSIP: 4525EP200) | $4,995,588 | 2.61% | 325,022 | Up ×1 | |||
| IVA Inventiva S.A. - American Depository Shares | $4,842,981 | 2.53% | 1,281,212 | $848,369 | Up ×1 | ||
| SABS SAB Biotherapeutics, Inc. - Common Stock | $4,198,654 | 2.20% | 1,076,578 | $312,179 | Up ×2 | ||
| OBIO Orchestra BioMed Holdings, Inc. - Ordinary Shares | $3,869,265 | 2.02% | 896,701 | $38,541 | |||
| CLDX Celldex Therapeutics, Inc. - Common Stock | $3,858,491 | 2.02% | 103,695 | $-276,638 | Down ×3 | ||
| ZVRA Zevra Therapeutics, Inc. - Common Stock | $3,635,821 | 1.90% | 253,544 | $995,023 | Down ×1 | ||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $3,515,226 | 1.84% | 357,966 | $289,110 | Down ×1 | ||
| FDMT 4D Molecular Therapeutics, Inc. - Common Stock | $3,360,298 | 1.76% | 252,654 | $-220,853 | Down ×1 | ||
| OVID Ovid Therapeutics Inc. - Common Stock | $3,000,797 | 1.57% | 1,115,538 | $963,011 | Up ×1 | ||
| EYPT EyePoint, Inc. - Common Stock | $2,741,954 | 1.43% | 191,745 | $-46,989 | Down ×1 | ||
| UPB Upstream Bio, Inc. - Common Stock | $2,424,692 | 1.27% | 350,389 | $-675,435 | Up ×1 | ||
| Unknown issuer (CUSIP: 811292309) | $2,211,955 | 1.16% | 543,478 | Up ×1 | |||
| SLN Silence Therapeutics Plc - American Depository Share | $2,105,228 | 1.10% | 191,733 | Up ×1 | |||
| LONA LeonaBio, Inc. - Common Stock | $1,371,874 | 0.72% | 149,279 | $-123,902 | |||
| MAZE Maze Therapeutics, Inc. - Common Stock | $1,306,932 | 0.68% | 43,798 | $-438 | |||
| CRVS Corvus Pharmaceuticals, Inc. - Common Stock | $1,051,477 | 0.55% | 70,380 | $-199,597 | Down ×1 | ||
| SGMT Sagimet Biosciences Inc. - Series A Common Stock | $973,037 | 0.51% | 125,878 | Up ×1 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
| Security | Value | % of portfolio | Streak |
|---|---|---|---|
| PHAT | $11,396,384 | 5.96% | up ×3 |
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| ACHV | Bought more | +248K | +$15.0M |
| CORT | Trimmed | -11K | +$5.8M |
| MIST | Bought more | +3.3M | +$4.9M |
| CMPS | Trimmed | -169K | +$4.0M |
| PALI | Bought more | +1.5M | +$3.4M |
| AQST | Bought more | +731K | +$3.0M |
| KYTX | Bought more | +239K | +$2.3M |
| PHAT | Bought more | +209K | +$2.0M |
| DCTH | Trimmed | -108K | +$1.8M |
| ZVRA | Trimmed | -29K | +$995K |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| AKRO | Dec. 31, 2025 | 228,884 | $10,867,412 | No longer tracked |
| MDGL | June 30, 2025 | 30,032 | $9,947,499 | 77.1% |
| APLT | Dec. 31, 2025 | 11,285,420 | $6,826,551 | No longer tracked |
| VOR | June 30, 2026 | 314,543 | $5,587,368 | 24.4% |
| RNA | June 30, 2025 | 178,500 | $5,269,320 | -52.0% |
| ARDX | March 31, 2025 | 950,947 | $4,821,301 | -18.0% |
| VRDN | June 30, 2026 | 210,163 | $4,087,734 | 31.5% |
| TCRX | Dec. 31, 2025 | 1,932,304 | $3,516,793 | -24.9% |
| NKTR | March 31, 2026 | 82,822 | $3,501,714 | 4.0% |
| OCS | June 30, 2026 | 122,223 | $3,279,243 | -4.3% |
| TRVI | June 30, 2026 | 223,802 | $2,647,064 | 0.1% |
| IMUX | June 30, 2026 | 2,344,779 | $2,620,262 | 7.7% |
| JSPR | Dec. 31, 2025 | 1,028,806 | $2,448,558 | -59.2% |
| CHRS | June 30, 2026 | 1,420,550 | $2,413,387 | -6.8% |
| KYMR | March 31, 2025 | 56,359 | $2,267,323 | 354.3% |
| SNDX | June 30, 2025 | 183,259 | $2,251,337 | 117.2% |
| KLRS | June 30, 2026 | 295,771 | $1,721,024 | 3.2% |
| QURE | June 30, 2026 | 104,772 | $1,713,022 | 4.0% |
| RGNX | March 31, 2026 | 116,896 | $1,683,302 | 36.1% |
| NUVB | June 30, 2026 | 329,296 | $1,412,680 | 23.8% |
| EVMN | June 30, 2026 | 55,664 | $1,279,715 | 8.9% |
| ALDX | June 30, 2026 | 730,606 | $1,234,724 | -26.3% |
| KURA | March 31, 2025 | 130,000 | $1,132,300 | 84.5% |
| LENZ | March 31, 2026 | 59,085 | $945,360 | -47.3% |
| CAPR | Sept. 30, 2025 | 70,000 | $695,100 | 3.9% |
| AARD | March 31, 2026 | 46,408 | $609,105 | 78.5% |
| CNTB | June 30, 2026 | 209,493 | $553,909 | 5.9% |
| ATHA | Sept. 30, 2025 | 1,492,792 | $450,823 | No longer tracked |
| CMPX | June 30, 2025 | 228,317 | $433,802 | -5.8% |
| JSPR | March 31, 2025 | 20,000 | $427,600 | -82.6% |
| EIGRQ | Sept. 30, 2025 | 146,381 | $423,000 | No longer tracked |
| CMPS | March 31, 2025 | 25,209 | $95,290 | 389.3% |
| MSLE | June 30, 2026 | 10,145 | $57,116 | 29.8% |